DESTINY EDITOpen EDIT

DESTINY EDIT · Funding notices

D-3Science and Technology and other Research and Development

DoW Rare Cancers Resource and Community Development Award

Agency
Department of Defense
Run by
JoAnn Martin Grantor
Target applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Application period
2026-06-17 ~ 2026-11-18
Contact
JoAnn Martin Grantor 301-619-2594
Open in EDIT and start the applicationView on Grants.govApplication site

Source: Grants.gov

How to apply

  1. Register your organization on SAM.gov to get a UEI (Unique Entity ID). It can take up to 10 business days to become active, and it must be renewed every year. SAM.gov
  2. Create a Grants.gov account and add an applicant profile with your UEI. The E-Business Point of Contact named in SAM.gov gives the person who submits the AOR role. Grants.gov
  3. On the opportunity page, select Apply to create a Workspace. Complete the SF-424 and the other required forms in Workspace. Opportunity page
  4. Attach the narrative documents the NOFO asks for (such as the Project Narrative, Project Abstract and Budget Justification) in Workspace. EDIT can draft them from your materials. Workspace
  5. Submit from Workspace, then check the status with your Grants.gov tracking number. Track my application

Overview

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Research supporting this funding opportunity should fill one of the following major gaps: Lack of research and clinical resources, including patient tissues, cell and tumor models. Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings. Lack of infrastructure for sharing data and other resources. Lack of therapeutics and mechanistic research to inform treatment development. Distinctive Features: Documentation of plans for engagement and partnerships with Patient Advocates throughout the life cycle of the research study from development of the research question through execution of the study. Community building and enhancement are key components. A description of the dissemination and sustainability of the platform for scientific and/or clinical and patient community is required. Preliminary data are not required but may be included to address feasibility. Estimated total funding: $5,600,000 Expected awards: 5 Opportunity number: HT942526RCRPRCDA